Business Wire

Pegasus Digital Mobility Acquisition Corp. Announces Redemption Results and Confirms Voluntary Payment Amount

27.7.2023 16:37:00 EEST | Business Wire | Press release

Share

Pegasus Digital Mobility Acquisition Corp. (NYSE: PGSS.U) (the "Company"), a special purpose acquisition company founded by Pegasus Digital Mobility Sponsor (the "Sponsor") and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination with one or more businesses or assets (a "Business Combination"), today announced that holders of 2,195,855 of the Company's Class A ordinary shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account in connection with the announcement of the further extension of the period of time the Company has to consummate its proposed Business Combination with Gebr. SCHMID GmbH (the "SCHMID Group") to December 31, 2023. As a result, approximately $53.7 million will be remaining in the Company's trust account. Following the redemption, the Company's remaining number of issued and outstanding Class A ordinary shares was 5,003,218.

Commencing on August 1, 2023 and paid on the first day of each month thereafter until the earliest of (i) the date on which the Company consummates a Business Combination or (ii) December 31, 2023, the Sponsor will deposit $150,096.54 per month into the Company's trust account, representing $0.03 (three U.S. cents) per Class A ordinary share then in issue. The contribution amount shall be made available and paid on a monthly basis after the issuance of a non-convertible unsecured promissory note from the Company to the Sponsor in connection therewith. Should the Company's Board determine that it will not be able to consummate the initial Business Combination by December 31, 2023 and that the Company shall instead liquidate, the Sponsor's obligation to continue to make such contributions shall immediately cease. If the Board determines that more time is needed to consummate the initial Business Combination, a shareholders' vote in an extraordinary general meeting will be required to change the second amended and restated memorandum and articles of association of the Company.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements involve predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to certain risks and uncertainties, including but not limited to:

  • the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed Business Combination with the SCHMID Group;
  • the outcome of any legal proceedings that may be instituted against the Company, the SCHMID Group, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto;
  • the inability to complete the Business Combination with the SCHMID Group due to the failure to obtain approval of the shareholders of the Company or to satisfy other conditions to closing;
  • changes to the proposed structure of the Business Combination with the SCHMID Group that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination;
  • the ability to meet stock exchange listing standards following the consummation of the Business Combination with the SCHMID Group;
  • the risk that the Business Combination disrupts current plans and operations of the Company or the SCHMID Group as a result of the announcement and consummation of the Business Combination with the SCHMID Group;
  • the ability to recognise the anticipated benefits of the Business Combination with the SCHMID Group, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees;
  • costs related to the Business Combination with the SCHMID Group;
  • changes in applicable laws or regulations and delays in obtaining, adverse conditions contained in, or the inability to obtain regulatory approvals required to complete the Business Combination with the SCHMID Group;
  • the possibility that the Company, the SCHMID Group or the combined company may be adversely affected by other economic, business, and/or competitive factors;
  • the estimates of expenses and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; and
  • other risks and uncertainties set forth in the section entitled "Risk Factors" in the Company's prospectus on Form S-1 approved by the SEC.

The foregoing list of factors is not exhaustive. The forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the SCHMID Group and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Copies of the Company's registration statement are available on the SEC’s website, www.sec.gov.

Additional Information and Where to Find It

INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ ANY DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of any documents (including any amendments or supplements thereto) filed with the SEC through the website maintained by the SEC at www.sec.gov or by directing a request to investor-relations@pegasusdm.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pegasus Contact Information
Investor Relations
investor-relations@pegasusdm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Signaloid Announces Appointment of Quantitative Finance and Cloud Veterans to Advisory Board and Senior Commercialization Roles14.9.2026 06:00:00 EEST | Press release

British technology company Signaloid today announced the appointment of three distinguished industry veterans to its advisory board and senior leadership roles, to strengthen the commercialization momentum behind its technology: Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading for the Fixed Income Division at Morgan Stanley, Dr. Nachiketh Potlapally, former Architect at Oracle Cloud Infrastructure, and Christian Roth, former Senior Director Enterprise Sales, Intel. Bringing deep expertise in quantitative finance and cloud infrastructure, the appointments build on Signaloid’s commercial traction momentum in Europe, Japan, and the United States. Dr. Lee, prior to his executive role at Morgan Stanley, served as Global Head of Quantitative Analytics at RBS and holds a Ph.D. in Theoretical Physics from the University of Cambridge. He is a co-founder of RLxPartners Ltd, and serves as an advisor to the Head of the Department of Physics at the University of Oxfo

SES’s Final Three O3b mPOWER Satellites Successfully Launched13.9.2026 23:22:00 EEST | Press release

SES today announced the successful launch of its eleventh, twelfth and thirteenth O3b mPOWER satellites, further expanding its second-generation medium Earth orbit (MEO) system designed to offer high-performance connectivity services around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260913914517/en/ SES’s Final Three O3b mPOWER Satellites Successfully Launched The three satellites launched at 2:49 pm local time aboard a SpaceX Falcon 9 rocket from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station. “This launch marks a defining milestone for SES as we complete the O3b mPOWER constellation and further strengthen our MEO capabilities,” said Adel Al-Saleh, CEO of SES. “More importantly, it reinforces our ability to deliver resilient, secure and scalable connectivity for customers around the world, helping governments, enterprises, cloud providers and mobility customers meet their most critical

Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize12.9.2026 22:27:00 EEST | Press release

From more than 134,000 registrations spanning 214 countries and economies, Nurse Agimol Pradeep from United Kingdom has been announced as the winner of the Aster Guardians Global Nursing Award 2026. A Senior Transplant Coordinator at King’s College Hospital and Honorary Senior Lecturer at the University of Salford, UK, she was recognised with USD 250,000 at a prestigious ceremony held in Kochi, India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260912257725/en/ Nurse Agimol Pradeep - Aster Guardians Global Nursing Award 2026 Winner (Photo: AETOSWire) Since its launch in 2021, the Aster Guardians Global Nursing Award has grown into a global platform that celebrates nurses who are advancing the profession and creating meaningful change. The award was presented by Shri V. D. Satheesan, Hon’ble Chief Minister of Keralam, in presence of Dr. Azad Moopen and Alisha Moopen. The ceremony also featured a special message from Dr. Te

Last Night, a Star-studded Evening Celebrating Moncler’s Fifth Avenue Flagship Ushered in a New Chapter in the Brand’s Enduring Love Story With New York12.9.2026 00:01:00 EEST | Press release

Last night, on occasion of the opening of Moncler’s largest-ever global flagship on Fifth Avenue, special guests including Cher, Julia Roberts, Anne Hathaway, Serena Williams, Future, Spike Lee, Jessica Chastain, Adrien Brody, Odell Beckham Jr., Maria Sharapova, Colin Kaepernick, Adriana Lima, Mark Ronson, Shaun White, Helena Christensen, Penn Badgley, Gus Kenworthy, Jordan Clarkson, Coco Rocha, François Arnaud, Gavin Casalegno, Jacob Whiteduck-Lavoie, Sam Nivola, Evan Mock, Sammi Cheng, Princess Olympia of Greece, Hiroshi Fujiwara, Daniel Arsham, Edward Enninful, Tobe and Fat Nwigwe, Joaquín Furriel, Lucas Pinheiro Braathen, Nic von Rupp, Daniel Humm, Juliana Awad, Mickalene Thomas, Questlove, Michael Rainey Jr., Pete Davidson, and Francis Mallmann came together to mark a new chapter in the brand’s decades-long relationship with New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904757149/en/ MONCLER FIFTH AVE

Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research11.9.2026 15:00:00 EEST | Press release

Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent international pharmaceutical group governed by a foundation, to license K Pro, Owkin’s AI Scientist, together with multimodal patient data to advance the company’s oncology research. Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams, within K Pro. This agreement is the next chapter in Owkin and Servier’s collaboration, their previous work together being in patient subgroup identification, also in oncology. K Pro is Owkin’s AI scientist. It brings multimodal patient data and specialized biological agentic AI to drive smarter and faster decision-making to each step of the pharmaceutical value chain. K Pro utilizes specialized biological tools, leveraging a decade of knowledge gained through pharmaceutical partnerships and st

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye